A Phase 3 interventional study of Sodium Fluoride Toothpaste and Amine Fluoride Toothpaste in Caries, sponsored by GlaxoSmithKline. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-29.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is to evaluate the effect of fluoride dentrifrices on enamel with artificial caries lesions in an in situ model
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
Sodium fluoride toothpaste
Drug: Sodium Fluoride Toothpaste
Amine Fluoride
Drug: Amine Fluoride Toothpaste
Dose response
Drug: 675 ppmf toothpaste
Sodium monofluorophosphate/sodium fluoride Toothpaste
Drug: Sodium monofluorophosphate/Sodium Fluoride Toothpaste
Drug: Placebo
Test product
Test product
test product
placebo and washout treatment
dose response
Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)
SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).
Time frame: Baseline to 14 days
Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF)
SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.
Time frame: Baseline to 14 days
Change From Baseline in Enamel Fluoride Uptake Potential
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
Time frame: Baseline to 14 days
Participants were recruited at the clinical site.
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 13 | 13 | 13 | 13 | 13 |
| Completed | 11 | 13 | 12 | 13 | 13 |
| Not completed | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 1 | 0 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 11 | 13 | 12 | 13 | 13 |
| Completed | 11 | 13 | 12 | 12 | 13 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 13 | 13 | 12 | 12 | 11 |
| Completed | 13 | 12 | 10 | 11 | 11 |
| Not completed | 0 | 1 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 13 | 12 | 10 | 11 | 11 |
| Completed | 13 | 12 | 10 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 12 | 8 | 12 | 13 | 12 |
| Completed | 12 | 7 | 12 | 13 | 11 |
| Not completed | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 1 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 12 | 7 | 12 | 13 | 11 |
| Completed | 12 | 7 | 12 | 13 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 10 | 11 | 11 | 10 | 13 |
| Completed | 10 | 10 | 11 | 10 | 12 |
| Not completed | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other reason | 0 | 0 | 0 | 0 | 1 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 10 | 10 | 11 | 10 | 12 |
| Completed | 10 | 10 | 11 | 10 | 12 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sodium Fluoride(NaF) Toothpaste[1426parts Per Million(Ppm)F] | Amine Fluoride(AmF) Toothpaste (1400ppmF) | Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Started | 9 | 12 | 11 | 11 | 10 |
| Completed | 9 | 12 | 11 | 11 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
SMH recovery test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Difference in percent SMH recovery was calculated by comparing study NaF toothpaste (1426ppmF) with reference AmF toothpaste (1400ppmF).
| Percentage SMHR | NaF Toothpaste (1426ppmF) | AmF Toothpaste (1400ppmF) |
|---|---|---|
| Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF) | 38.05 ± 2.52 | 41.06 ± 2.53 |
SMH test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Differences in percent SMH recovery due to study and reference toothpastes were calculated.
| Percentage SMHR | NaF Toothpaste (1426ppmF) | AmF Toothpaste (1400ppmF) | NaMFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Percent SMH Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste (1400ppm F) and Placebo (0ppmF) | 38.05 ± 2.52 | 41.06 ± 2.53 | 33.48 ± 2.49 | 29.08 ± 2.50 | 14.49 ± 2.48 |
Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.
| micrograms (μg)* F/centimeters(cm)^2 | NaF Toothpaste (1426ppmF) | AmF Toothpaste (1400ppmF) | Na MFP/NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) |
|---|---|---|---|---|---|
| Change From Baseline in Enamel Fluoride Uptake Potential | 2342.35 ± 123.65 | 2305.11 ± 123.83 | 1809.74 ± 121.83 | 1649.44 ± 121.93 | 462.95 ± 120.92 |
Collected over All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| NaF Toothpaste (1426ppmF) | — | 0/57 (0%) | 1/57 (1.8%) |
| AmF Toothpaste (1400ppmF) | — | 0/57 (0%) | 5/57 (8.8%) |
| NaMFP/ NaF Toothpaste (1450ppmF) | — | 0/59 (0%) | 0/59 (0%) |
| NaF Toothpaste (675ppmF) | — | 0/59 (0%) | 3/59 (5.1%) |
| Placebo Toothpaste (0ppmF) | — | 0/59 (0%) | 2/59 (3.4%) |
| Overall | — | 0/65 (0%) | 10/65 (15.4%) |
| Event | NaF Toothpaste (1426ppmF) | AmF Toothpaste (1400ppmF) | NaMFP/ NaF Toothpaste (1450ppmF) | NaF Toothpaste (675ppmF) | Placebo Toothpaste (0ppmF) | Overall |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/57 | 5/57 | 0/59 | 3/59 | 2/59 | 10/65 |
| Age Continuous(years) | All Randomized Participants |
|---|---|
| Mean | 67.0 ± 9.97 |
| Sex: Female, Male(Participants) | All Randomized Participants |
|---|---|
| Female | 41 |
| Male | 24 |
| Region of Enrollment(participants) | All Randomized Participants |
|---|---|
| United States | 65 |
No study locations are listed for this record.
The record gives a start of Nov 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2013, 4 years 4 months after primary completion. A results delay was requested in Nov 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Fluoride